Baker McKenzie advised LSP (Life Science Partners) on the successful closing of a EUR 20 million Series A equity financing round into Innovative Molecules as the lead investor.
Innovative Molecules GmbH receives EUR 20 million equity financing to advance its preclinical product candidate IM-250 for the treatment of herpes simplex diseases. The company will use the funds to advance its lead compound from the current late preclinical stage into a phase 2 proof-of Concept clinical study.
IM-250 is a potent inhibitor of Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2) replication. The compound targets the helicase-primase enzyme complex of the virus. Due to its demonstrated impact on the viral reservoir in preclinical studies, IM-250 may become a game-changer for the treatment of HSV-related diseases with its potential to alter the natural course of the disease.
"Our long-standing client LSP leads the investment consortium in Innovative Molecules. As part of our advisory services, we can help contribute paving the way to address urgent medical needs in Herpes-induced diseases," comments Berthold A. Hummel, lead partner in the transaction.
Innovative Molecules GmbH currently based in Bad Salzuflen, with future business seat in Munich, is a drug development company aiming for setting a new treatment standard for Herpes simplex induced diseases.
LSP (Life Science Partners) based in Amsterdam and offices in Munich and Boston is one of the largest European investment funds providing financing for life sciences and health care companies. LSP’s management has raised over EUR 2 billion (USD 2.3 billion) and developed more than 120 companies since it started to invest in 1988.
Baker McKenzie's Corporate / M&A and life science team regularly advises big pharma, financial investors and early stage biotech companies on domestic and international healthcare transactions.
Most recently, Baker McKenzie advised Numab Therapeutics on CHF 100 million Series C Financing, CatalYm on a EUR 50 million Series B financing led by Vesalius Capital to advance its immunoncology development, Casdin Capital on a USD 50 million extension of the Series B Equity Financing in DNA Script, Chr. Hansen Holding on the acquisition of Jennewein Biotechnologie, BioMedPartners on its Series A Equity Financing of € 10.7 million in Tubulis, CureVac on its strategic mRNA technology collaboration with GSK, LSP Life Science Partners on a USD 38.5 Million Series B Financing in DNA Script, listed 4SC AG on a capital increase and international private placement, Galapagos on its 10 year global research and development collaboration with Gilead, MODAG on a € 12 million Series A Financing, Hitachi Chemical Company, Tokyo on the take-over of German apceth Biopharma, Forbion as lead investor on a € 17 million Series C Equity Financing of Omeicos Therapeutics as well as on a USD 54 million Series A Equity Financing of Gotham Therapeutics Corporation, Mundipharma on the sale of its Limburg production, CureVac AG on a collaboration with Eli Lilly and Hillhouse Capital as co-investor in the € 50 million Series C financing of Hookipa Biotech.
Legal advisor to LSP:
Corporate/M&A: Berthold A. Hummel (partner, Munich)
Corporate/M&A: Julia Braun (counsel, Munich), Dr. Julia Rossié (associate, Munich), Marianne Milovanov (associate, Munich)
Antitrust: Dr. Christian Burholt (partner, Berlin), Katrin Kurz (associate, Berlin)
Employment: Dr. Matthias Köhler (partner, Berlin)
Public Law: Anahita Thoms (partner, Dusseldorf)
IP: Dr. Markus Hecht (senior associate, Frankfurt), Dr. Julia Schieber (senior associate, Zurich)
Pharma: Dr. Martin Altschwager (senior associate, Frankfurt), Dr. Dorothea Radtke (associate, Frankfurt)